144 related articles for article (PubMed ID: 7542685)
21. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
22. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.
Ho GY; Studentsov YY; Bierman R; Burk RD
Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):110-6. PubMed ID: 14744741
[TBL] [Abstract][Full Text] [Related]
23. Capture ElISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in patients with anogenital warts.
Peng S; Qi Y; Christensen N; Hengst K; Kennedy L; Frazer IH; Tindle RW
Pathology; 1999 Nov; 31(4):418-22. PubMed ID: 10643018
[TBL] [Abstract][Full Text] [Related]
24. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
[TBL] [Abstract][Full Text] [Related]
25. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
27. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
28. A two-site enzyme immunoassay for quantitation of human papillomavirus type 16 particles.
Eklund C; Dillner J
J Virol Methods; 1995 May; 53(1):11-23. PubMed ID: 7635919
[TBL] [Abstract][Full Text] [Related]
29. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females.
Matsumoto K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Jpn J Cancer Res; 1997 Apr; 88(4):369-75. PubMed ID: 9197528
[TBL] [Abstract][Full Text] [Related]
30. Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia.
Kanda T; Teshima H; Katase K; Umezawa S; Watabe H; Takahashi H; Onda T; Yoshiike K
Intervirology; 1995; 38(3-4):187-91. PubMed ID: 8682615
[TBL] [Abstract][Full Text] [Related]
31. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia.
Einstein MH; Studentsov YY; Ho GY; Fazzari M; Marks M; Kadish AS; Goldberg GL; Runowicz CD; Burk RD
Int J Cancer; 2007 Jan; 120(1):55-9. PubMed ID: 17036320
[TBL] [Abstract][Full Text] [Related]
32. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
[TBL] [Abstract][Full Text] [Related]
33. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
34. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
[TBL] [Abstract][Full Text] [Related]
35. Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein.
Sapp M; Kraus U; Volpers C; Snijders PJ; Walboomers JM; Streeck RE
J Gen Virol; 1994 Dec; 75 ( Pt 12)():3375-83. PubMed ID: 7996132
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of HPV-DNA and anti-HPV antibodies in women from Girardot, Colombia.
Leon S; Sánchez R; Patarroyo MA; Camargo M; Mejia A; Urquiza M; Patarroyo ME
Sex Transm Dis; 2009 May; 36(5):290-6. PubMed ID: 19295467
[TBL] [Abstract][Full Text] [Related]
37. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children.
Cason J; Kambo PK; Best JM; McCance DJ
Int J Cancer; 1992 Feb; 50(3):349-55. PubMed ID: 1310487
[TBL] [Abstract][Full Text] [Related]
38. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
[TBL] [Abstract][Full Text] [Related]
39. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
[TBL] [Abstract][Full Text] [Related]
40. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
